News | November 18, 2024
Richard Manning provided trial testimony that contributed to a decisive legal victory for biotech startup Inhibrx in a $460 million trade secrets case brought by I-Mab Biopharma in Delaware federal district court.
Dr. Richard Manning’s expertise includes economic valuation and damages, intellectual property, breach of contract, fraud, and other commercial litigation. He provides testimony and consultation in all these areas and on securities litigation, tax, antitrust and competition, and public policy.
Washington, DC
Richard Manning provides insights based on economic theory and data analysis to help clients solve complex problems arising in a variety of business settings with an emphasis on biopharmaceuticals in both prescription and OTC settings, medical devices, life sciences, and animal health.
Dr. Manning has testified in U.S. District Court, U.S. Bankruptcy Court, the Delaware Court of Chancery, the United States Patent Trial and Appeals Board, and the International Chamber of Commerce. He has served as a consulting expert and prepared reports and commentary on a wide range of issues in the biopharmaceutical (both innovative and follow-on sectors) and healthcare industries. His career includes 14 years as an executive in multinational pharmaceutical companies, where he led economic analysis and strategy development to shape practices on emerging business concerns.
Examples of Dr. Manning’s work include:
Before joining Secretariat, Dr. Manning was a managing director at Intensity. Previously, he was a partner at Bates White, an economic consulting firm offering analysis and expert testimony services to law firms, Fortune 500 companies, and government agencies. Dr. Manning was executive director at Merck, a senior director at Pfizer, and a director at PricewaterhouseCoopers.
Dr. Manning was an economics professor at Brigham Young University and a visiting professor at the Graduate School of Business at the University of Chicago. As an academic, his teaching and research focused on price theory, the economic analysis of law, industrial organization, and the economics of government regulation.
Richard Manning provided trial testimony that contributed to a decisive legal victory for biotech startup Inhibrx in a $460 million trade secrets case brought by I-Mab Biopharma in Delaware federal district court.
Secretariat and Nine Experts Recognized in the 2024 IAM Patent 1000
Nine Secretariat intellectual property experts have been recognized as leading patent litigation expert witnesses in the eleventh edition of the IAM Patent 1000.
How Much Will Covering Anti-Obesity Drugs Cost Medicare? Accounting for Commonly Overlooked Effects
By Richard Manning and Fred Selck A new class of anti-obesity medications (AOMs) called GLP-1s have been shown to be highly effective at helping people lose weight. Given the efficacy of GLP-1s, and the significant long-term costs associated with treating obesity and its related diseases, there is increasing pressure on public and private health insurers […]